Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CEST

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
06/23 CVS HEALTH : appeals to the City Council in its effort to move into Laguna Drug ..
06/21 CVS HEALTH : Points of Light Recognizes CVS Health As One Of The 50 Most Communi..
06/21 CVS : Experts Discuss How Medicaid Innovations Reduce Costs and Increase Access ..
06/21 CVS HEALTH : Monroe County's tax battle with CVS not over
06/19 CVS HEALTH : Today's Research Reports on Stocks to Watch: CVS Health and Walgree..
06/16 CVS : By the Numbers: Real-World Impact of Rising Drug Costs
06/15 CVS HEALTH : Pharmacy Now Using Time Delay Safes in Ohio for Controlled Substanc..
06/14 CVS HEALTH : Medicaid as a Driver of Care Innovation
06/13 CVS HEALTH : Joins Drug Store News and Mack Elevation in Convening Health Innova..
06/13 CVS : Protecting Consumers in an Environment of Rising Drug Prices
More news
Sector news : Drug Retailers - NEC
06/22DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens to Settle -- WSJ
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit--Upd..
06/21 STADA ARZNEIMITTEL : Low acceptances leave Stada bid down to the wire
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit
06/20 U.S. Supreme Court again limits where companies can be sued
More sector news : Drug Retailers - NEC
News from SeekingAlpha
06/23 The MnM Portfolio, June 2017 Supplement - How Amazon-Proof Is The Portfolio?
06/23 AMAZON PURCHASES WHOLE FOODS : The Global Context
06/22 U.S Oil, The Permian And Global Outlook
06/21 Buying Dividend Growth Stocks Without Looking - More Than 2 Years Later
06/21 PREMARKET GAINERS AS OF 9 : 05 am
Advertisement
Financials ($)
Sales 2017 184 206 M
EBIT 2017 10 161 M
Net income 2017 5 384 M
Debt 2017 24 614 M
Yield 2017 2,54%
P/E ratio 2017 15,02
P/E ratio 2018 13,29
EV / Sales 2017 0,56x
EV / Sales 2018 0,53x
Capitalization 78 865 M
More Financials
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 87,1 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-1.90%78 865
WALGREENS BOOTS ALLIAN..-7.76%82 520
EXPRESS SCRIPTS HOLDIN..-5.19%39 152
MCKESSON CORPORATION18.88%35 305
CARDINAL HEALTH INC9.42%25 170
AMERISOURCEBERGEN CORP..23.25%20 923
More Results